You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 4, 2024

Details for Patent: 9,186,344

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 9,186,344 protect, and when does it expire?

Patent 9,186,344 protects DOJOLVI and is included in one NDA.

This patent has eight patent family members in four countries.

Summary for Patent: 9,186,344

Title:	Glycogen or polysaccharide storage disease treatment method
Abstract:	A method for treating glycogen storage disease by administering an effective amount of a composition that includes ketogenic odd carbon fatty acids that ameliorate the symptoms of these diseases.
Inventor(s):	Roe; Charles R. (Rockwell, TX)
Assignee:	BAYLOR RESEARCH INSTITUTE (Dallas, TX)
Application Number:	14/214,317
Patent Claim Types: see list of patent claims	Composition; Formulation; Delivery;

Drugs Protected by US Patent 9,186,344

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Ultragenyx Pharm Inc	DOJOLVI	triheptanoin	LIQUID;ORAL	213687-001	Jun 30, 2020		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 9,186,344

Subscribe to access the full database, or Sign Up
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	2573054	⤷ Sign Up
Canada	2784420	⤷ Sign Up
Canada	2784585	⤷ Sign Up
European Patent Office	1773317	⤷ Sign Up
European Patent Office	3300727	⤷ Sign Up
Mexico	2007000304	⤷ Sign Up
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.